Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years

Acta Neurologica Belgica

Volumn 114, Issue 4, 2014, Pages 285-291

  Streitová, Hana ^a   Bareš, Martin ^a,b  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Blepharospasm; Botulinum toxin; Hemifacial spasm; Long term therapy; Quality of life

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSKINESIA; FACIAL NERVE PARALYSIS; FEMALE; HEMIFACIAL SPASM; HUMAN; LONG TERM CARE; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PTOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84912044515     PISSN: 03009009     EISSN: 22402993     Source Type: Journal    
DOI: 10.1007/s13760-014-0285-z     Document Type: Article

References (17)

1. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y (2008) Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70(19):1699–1706
2. Hallett M, Evinger C, Jankovic J, Stacy M (2008) BEBRF international workshop. Update on blepharospasm: report from the BEBRF international workshop. Neurology 71(16):1275–1282
3. Jankovic J, Schwarz K, Donova DT (1990) Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatr 64:751–757
4. Ortisi E, Henderson HWA, Bunce C, Xing W, Collin JRO (2006) Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases. Eye 20(8):916–922
5. Jost WH, Kohl A (2001) Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 248(Suppl 1):I/21–I/24
6. Rollnik JD, Matzke M, Wohlfarth K, Dengler HB (2000) Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. Eur Neurol 43:9–12
7. Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F (2002) Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 249:64–68
8. Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA (2013) Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol 156(1):173–177
9. Tucha O, Naumann M, Berg D, Alders GL, Lange KW (2001) Quality of life in patients with blepharospasm. Acta Neurol Scand 103:49–52
10. Kaňovský P, Bareš M, Streitová H, Pospíšilová D, Dufek M (1996) Socioeconomic aspects of the treatment of facial dyskinesias with botulinum toxin A. Czech Slov Neurol Neurochir 59/92(3):148–151
11. Kenney C, Jankovic J (2008) Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 115(4):585–591
12. Reimer J, Gilg K, Karow A, Esser J, Franke GH (2005) Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 111(1):64–70
13. Lasalvia CG, Pereira Led S, da Cunha MC, Kitadai SP (2006) Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm. Arq Bras Oftalmol 69(5):701–705
14. Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22(4):265–273
15. Batla A, Stamelou M, Bhatia KP (2012) Treatment of focal dystonia. Curr Treat Options Neurol 14(3):213–229
16. Ababneh OH, Cetinkaya A, Kulwin DR (2013) Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. doi:10.1111/ceo.12165
17. Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin A type A injections. Funct Neurol 22(2):95–100